{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:34:27Z","timestamp":1792424067354,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)\u2014a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and\/or BCL6 rearrangements (\"double hit\"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase &amp;gt;3\u00a0\u00d7 upper limit of normal, and a dual-expressor immunophenotype. Age &amp;gt;60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009731","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T10:24:19Z","timestamp":1683887059000},"page":"6381-6394","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["High-grade B-cell lymphoma, not otherwise specified: a\u00a0multi-institutional retrospective study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-2069","authenticated-orcid":false,"given":"Adam S.","family":"Zayac","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, The Warren Alpert Medical School Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5077-4181","authenticated-orcid":false,"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-1077","authenticated-orcid":false,"given":"Mitchell E.","family":"Hughes","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Bock","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S.","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-4507","authenticated-orcid":false,"given":"Emily C.","family":"Ayers","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-4583","authenticated-orcid":false,"given":"Mark","family":"Girton","sequence":"additional","affiliation":[{"name":"5Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-7207","authenticated-orcid":false,"given":"Marie","family":"Hu","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Beckman","sequence":"additional","affiliation":[{"name":"7Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0523","authenticated-orcid":false,"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[{"name":"8Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-8006","authenticated-orcid":false,"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"8Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Chang","sequence":"additional","affiliation":[{"name":"9Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Stepanovic","sequence":"additional","affiliation":[{"name":"9Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4579-3003","authenticated-orcid":false,"given":"Habibe","family":"Kurt","sequence":"additional","affiliation":[{"name":"10Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Sandoval-Sus","sequence":"additional","affiliation":[{"name":"11Department of Malignant Hematology and Cellular Therapy, Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ali","family":"Ansari-Lari","sequence":"additional","affiliation":[{"name":"12Department of Pathology, Memorial Healthcare System, Hollywood, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin K.","family":"Kothari","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kress","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina L.","family":"Xu","sequence":"additional","affiliation":[{"name":"14Department of Pathology and Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-5883","authenticated-orcid":false,"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[{"name":"15Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-8226","authenticated-orcid":false,"given":"Suchitra","family":"Sundaram","sequence":"additional","affiliation":[{"name":"15Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"16Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"},{"name":"17Division of Medical Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3807-3638","authenticated-orcid":false,"given":"Kikkeri N.","family":"Naresh","sequence":"additional","affiliation":[{"name":"18Department of Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2648-4448","authenticated-orcid":false,"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[{"name":"19Division of Hematology-Oncology, University of Michigan Health, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"20The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David A.","family":"Bond","sequence":"additional","affiliation":[{"name":"20The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-9891","authenticated-orcid":false,"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahak","family":"Saad","sequence":"additional","affiliation":[{"name":"21Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"22Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Pandya","sequence":"additional","affiliation":[{"name":"22Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-151X","authenticated-orcid":false,"given":"Seema G.","family":"Naik","sequence":"additional","affiliation":[{"name":"23Penn State Cancer Institute, Penn State Hershey Medical Center, Hershey, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-152X","authenticated-orcid":false,"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"24Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-0615","authenticated-orcid":false,"given":"Bradley","family":"Haverkos","sequence":"additional","affiliation":[{"name":"24Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"25Division of Hematology and Oncology, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-4416","authenticated-orcid":false,"given":"Timothy S.","family":"Oh","sequence":"additional","affiliation":[{"name":"25Division of Hematology and Oncology, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1015-7434","authenticated-orcid":false,"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"26Department of Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Nutsch","sequence":"additional","affiliation":[{"name":"26Department of Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0724-461X","authenticated-orcid":false,"given":"Paul G.","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"27Department of Medicine, Section of Hematology-Oncology, University of Illinois, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"27Department of Medicine, Section of Hematology-Oncology, University of Illinois, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, The Warren Alpert Medical School Medical School of Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"issue":"7","key":"2023111414304516100_bib1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023111414304516100_bib2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2023111414304516100_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.2020008374","article-title":"Defining and treating high-grade B-cell lymphoma, NOS","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2023111414304516100_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2023111414304516100_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2023111414304516100_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt lymphoma international prognostic index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023111414304516100_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12343","article-title":"B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: study of 39 cases","volume":"162","author":"Perry","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"2023111414304516100_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PAS.0000000000000147","article-title":"Clinical significance of MYC expression and\/or \"high-grade\" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study","volume":"38","author":"Cook","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2023111414304516100_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s12185-016-1989-z","article-title":"Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"103","author":"Miyamoto","year":"2016","journal-title":"Int J Hematol"},{"issue":"1","key":"2023111414304516100_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/10428194.2019.1654097","article-title":"Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma","volume":"61","author":"Decker","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2023111414304516100_bib11","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2147\/CMAR.S243753","article-title":"High-grade B-cell lymphomas, not otherwise specified: a study of 41 cases","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2023111414304516100_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00428-021-03050-4","article-title":"The \"Burkitt-like\" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS","volume":"479","author":"Huttl","year":"2021","journal-title":"Virchows Arch"},{"issue":"suppl 2","key":"2023111414304516100_bib13","first-page":"111","article-title":"Characterization of the genetic landscape of high-grade B-cell lymphoma, NOS\u2013 an LLMPP project","volume":"39","author":"Collinge","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"2023111414304516100_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-022-03404-6","article-title":"Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma","volume":"482","author":"King","year":"2023","journal-title":"Virchows Arch"},{"issue":"9","key":"2023111414304516100_bib15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"2023111414304516100_bib16","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"22","key":"2023111414304516100_bib17","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1182\/bloodadvances.2022007475","article-title":"Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma","volume":"6","author":"Ferreri","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023111414304516100_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"19","key":"2023111414304516100_bib19","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"15","key":"2023111414304516100_bib20","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023111414304516100_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2020006926","article-title":"Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers","volume":"137","author":"Evens","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2023111414304516100_bib22","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A\u00a0prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2023111414304516100_bib23","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"27","key":"2023111414304516100_bib24","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023111414304516100_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"issue":"suppl 1","key":"2023111414304516100_bib26","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1182\/blood-2022-157105","article-title":"High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS): central nervous system (CNS) involvement, prophylaxis, and recurrence risk in a multi-institutional series","volume":"140","author":"Epperla","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023111414304516100_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023111414304516100_bib28","first-page":"2493","article-title":"Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population","volume":"141","author":"Alduaij","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2023111414304516100_bib29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41375-022-01778-9","article-title":"High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL\/HGBL-DH than DLBCL","volume":"37","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"20","key":"2023111414304516100_bib30","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2023111414304516100_bib31","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","volume":"137","author":"Ollila","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2023111414304516100_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A\u00a0probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"35","key":"2023111414304516100_bib33","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023111414304516100_bib34","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"2023111414304516100_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"6","key":"2023111414304516100_bib36","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1158\/1078-0432.CCR-20-2378","article-title":"Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP","volume":"27","author":"Song","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023111414304516100_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1541-7786.MCR-20-0466","article-title":"Aggressive B-cell lymphoma with MYC\/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents","volume":"19","author":"Deng","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"22","key":"2023111414304516100_bib38","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023111414304516100_bib39","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3324\/haematol.2021.278638","article-title":"Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome","volume":"107","author":"Dodero","year":"2022","journal-title":"Haematologica"},{"issue":"20","key":"2023111414304516100_bib40","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023111414304516100_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/hematology.2021000247","article-title":"Double-hit lymphoma: optimizing therapy","volume":"2021","author":"Dunleavy","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2023111414304516100_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023111414304516100_bib43","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"issue":"S2","key":"2023111414304516100_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.27_2879","article-title":"Biomarker-driven treatment strategy in high risk diffuse large b-cell lymphoma: results of a nordic phase 2 study","volume":"39","author":"Lepp\u00e4","year":"2021","journal-title":"Hematol Oncol"},{"issue":"4","key":"2023111414304516100_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"2023111414304516100_bib46","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"2023111414304516100_bib47","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2023111414304516100_bib48","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"13","key":"2023111414304516100_bib49","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood.2022016226","article-title":"CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights","volume":"140","author":"Ali","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6381\/2089146\/blooda_adv-2023-009731-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6381\/2089146\/blooda_adv-2023-009731-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T09:31:15Z","timestamp":1699954275000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6381\/495790\/High-grade-B-cell-lymphoma-not-otherwise-specified"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":49,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009731","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}